secwatch.observer — SEC 8-K summary
======================================

Issuer:     Imunon, Inc. (IMNN)
CIK:        0000749647
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001493152-24-031882
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imunon reports positive Phase 2 OS data for IMNN-001; net loss narrows in Q2 2024
--------------------------------------------------------------------------------

- Q2 net loss of $4.8M ($0.51/share) vs $5.6M ($0.61/share) in Q2 2023; operating expenses down 8%.
- Positive OVATION 2 topline: 11.1-month median OS improvement (HR=0.74) in ITT; 15.7-month gain in per-protocol (HR=0.64).
- Phase 3 study of IMNN-001 planned to start Q1 2025 after End-of-Phase 2 FDA meeting.
- Raised $10M gross ($9M net) in July 2024 registered direct offering; cash + investments $5.3M at June 30, funding into Q3 2025.
- IMNN-101 Phase 1 COVID booster trial enrolling; topline data expected by year-end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/749647/000149315224031882/0001493152-24-031882-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/749647/000149315224031882/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-031882

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer